Sunday, June 22, 2025 6/22/2025

INFRARED & X-RAY NANOGOLD THERAPY OF HEAD & NECK CANCERS

Award Number: R44CA130225
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2008
PERIOD OF PERFORMANCE END DATE: 03/31/2013

Group Awards By:

View Award Description

INFRARED & X-RAY NANOGOLD THERAPY OF HEAD & NECK CANCERS - DESCRIPTION (provided by applicant): This proposal is based on a recent discovery that tumors can bioconvert non-absorbing small metal nanoparticles into intense infrared (IR) absorbers. In preliminary tests, non-IR absorbing 15 nm gold nanoparticles were immunotargeted to human tumors in mice which then became highly IR absorbing. The amplification factor in IR absorption can be a factor of 20 or more, which is not accessible by use of other much larger nanoparticles (~130 nm) that are designed to initially absorb IR. This factor greatly enhances the tumor- to-non-tumor distinction. The small size also enhances tumor uptake. Treatment with IR led to rapid and complete tumor ablation in 1 cm tumors, whereas the tumors were not controlled in irradiated mice without the gold. This new IR bioamplification process will be studied and optimized to treat squamous cell carcinomas, which comprise 90% of head and neck cancers. Epidermal growth factor receptors (EGFr) are overexpressed by these tumors and covalent anti-EGFr antibody-gold conjugates will be used for targeting human A431 tumors in mice. A microscopic study will document tumor and normal tissue responses. In Phase II, this novel therapy will be optimized with respect to gold size and targeting ligand. The IR hyperthermia therapy will then be combined with radiotherapy, since we have recently shown that hyperthermia and x-rays are highly synergistic in treating squamous cell carcinomas. The new combination therapy should better avoid damage to salivary glands and surrounding normal tissue, which is one of the serious side effects of current therapies. In order to demonstrate safety and safety limits, an acute, subacute, and long-term toxicity study will be conducted. Work will culminate in a product for FDA approval of clinical trials. If successful, this new approach could improve the treatment of head and neck as well as other cancers. PUBLIC HEALTH RELEVANCE: A novel cancer treatment using nanotechnology has recently been developed that is very promising in preliminary animal studies. It also may be used for sensitive early detection of tumors and enable image guided interventions. If successful, it could improve detection and treatment of head and neck tumors as well as other cancers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $387,288 )
2012	2012	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	000	3	3/28/2012	NON-COMPETING CONTINUATION	$387,288
														Subtotal = $387,288

Issue Date FY: 2011 ( Subtotal = $399,704 )
2011	2011	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	001	2	3/25/2011	EXTENSION WITH OR WITHOUT FUNDS	$399,704
2011	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	000	1	3/22/2011	NEW	$0
														Subtotal = $399,704

Issue Date FY: 2010 ( Subtotal = $0 )
2010	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	000	1	9/24/2010	NEW	$0
														Subtotal = $0

Issue Date FY: 2009 ( Subtotal = $0 )
2009	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	000	1	1/7/2009	NEW	$0
														Subtotal = $0

Issue Date FY: 2008 ( Subtotal = $199,947 )
2008	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Treatment Research	000	1	8/19/2008	NEW	$199,947
														Subtotal = $199,947

Grand Total All Awards = $986,939

Top

All Categories

About

Search

Reports

Data Submission

Award Information

INFRARED & X-RAY NANOGOLD THERAPY OF HEAD & NECK CANCERS

Award Number: R44CA130225

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2008

PERIOD OF PERFORMANCE END DATE: 03/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer